In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition

• References

• 1 Serebruany VL, Malinin AI, Atar D. et al. Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. Am Heart J 2007; 153: 371-377.
• 2 Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009; 07: 651-657.
• 3 Hemker HC, Giesen P, AlDieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
• 4 Altman R, Scazziota A, De Lourdes Herrera M. et al. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006; 04: 2022-2027.
• 5 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
• 6 Sumner WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 1996; 81: 533-543.
• 7 Armstrong P, Dhanji A, Truss N. et al. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost 2009; 102: 772-778.
• 8 Ferreiro JL, DJ A. Clopidogrel response variability: Current status and future directions. Thromb Haemost 2009; 102: 7-14.
• 9 Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation 2005; 112: 2725-2734.
• 10 Kahn ML, Nakanishi-Matsui M, Shapiro MJ. et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-887.
• 11 Mayer SA, Schwab S. Advances in critical care and emergency medicine 2007. Stroke 2008; 39: 261-263.
• 12 Romagnoli S, Bevilacqua S, Gelsomino S. et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006; 102: 1320-1326.
• 13 Bal Dit Sollier C, Berge N, Boval B. et al. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost 2009; 101: 116-122.
• 14 Wong PC, Crain EJ, Watson CA. et al. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thromb Haemost 2009; 101: 108-115.
• 15 Serebruany V, Shalito I, Kopyleva O. Prasugrel development – claims and achievements. Thromb Haemost 2009; 101: 14-22.